Clinical Trial Update: A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia [Phase 2]

View source ↗

Summary

TAK-079 was studied in adults with persistent or chronic primary immune thrombocytopenia in a Phase 2 trial. The study is completed and results have been posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• TAK-079

Snippet

Sponsor: Takeda | Conditions: Primary Immune Thrombocytopenia | Phase 2 | Status: COMPLETED | Results posted: 2025-06-15